Cargando…

Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer

IMPORTANCE: A large proportion of patients with breast cancer concomitantly use adjuvant hormone therapy and cardiovascular therapy. OBJECTIVE: To examine the relative risk of discontinuing cardiovascular therapy during the periods before and after discontinuation of adjuvant hormone therapy. DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Wei, Zeng, Erwei, Sjölander, Arvid, Hübbert, Laila, Hedayati, Elham, Czene, Kamila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352860/ https://www.ncbi.nlm.nih.gov/pubmed/37459096 http://dx.doi.org/10.1001/jamanetworkopen.2023.23752

Ejemplares similares

Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer
por: Zeng, Erwei, et al.
Publicado: (2022)

Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening
por: He, Wei, et al.
Publicado: (2019)

Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study
por: Hubbert, Laila, et al.
Publicado: (2023)

Analysis of Breast Cancer Family History, Estrogen Receptor Status, and Breast Cancer Outcomes in Sweden
por: Zhang, Yuqi, et al.
Publicado: (2023)

Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
por: Altena, Renske, et al.
Publicado: (2021)

Mammographic microcalcifications and risk of breast cancer
por: Azam, Shadi, et al.
Publicado: (2021)

Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer
por: Eriksson, Louise, et al.
Publicado: (2019)

The early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients
por: Taketani, Kenji, et al.
Publicado: (2013)

Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Breast Cancer: Evidence from a General Female Population and a Mammographic Screening Cohort in Sweden
por: Hu, Kejia, et al.
Publicado: (2023)

Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skåne, Sweden
por: Shen, Qing, et al.
Publicado: (2019)

Risk of heart disease following treatment for breast cancer – results from a population-based cohort study
por: Yang, Haomin, et al.
Publicado: (2022)

Determinants of Mammographic Density Change
por: Azam, Shadi, et al.
Publicado: (2019)

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials
por: Ahmed, Nibras, et al.
Publicado: (2022)

Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden
por: Johansson, Annelie, et al.
Publicado: (2021)

Mortality Among Patients Undergoing Blood Transfusion in Relation to Donor Sex and Parity: A Natural Experiment
por: Zhao, Jingcheng, et al.
Publicado: (2022)

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
por: Fu, Fangmeng, et al.
Publicado: (2022)

Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer
por: Hu, Xin, et al.
Publicado: (2022)

Predictors of mammographic microcalcifications
por: Azam, Shadi, et al.
Publicado: (2020)

Background risk of breast cancer and the association between physical activity and mammographic density
por: Trinh, Thang, et al.
Publicado: (2015)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Statin Discontinuation and Cardiovascular Events Among Older People in Denmark
por: Thompson, Wade, et al.
Publicado: (2021)

3365 Treatment Interruptions and Early Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients
por: Mao, Daqin, et al.
Publicado: (2019)

On the relationship between the heritability and the attributable fraction
por: Dahlqwist, Elisabeth, et al.
Publicado: (2019)

Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers
por: Wang, Qiao-Li, et al.
Publicado: (2023)

Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy?
por: Rosenberg, L, et al.
Publicado: (2009)

Progressive multifocal leukoencephalopathy after heart transplantation: 4 years of clinically stable infection on low-dose immunosuppressive therapy
por: Sundbom, Per, et al.
Publicado: (2017)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy
por: Rea, Federico, et al.
Publicado: (2021)

Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer
por: Branigan, Gregory L., et al.
Publicado: (2020)

Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer
por: Thomas, Cecilia E., et al.
Publicado: (2022)

Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non–Small Cell Lung Cancers
por: Parsons, Scott, et al.
Publicado: (2020)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

pS2 and response to adjuvant hormone therapy in primary breast cancer.
por: Spyratos, F., et al.
Publicado: (1994)

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices
por: Shaikh, Asim Jamal, et al.
Publicado: (2012)

Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy
por: Kate, Anahita, et al.
Publicado: (2016)

Practical consensus recommendations on duration of adjuvant hormonal therapy in breast cancer
por: Gupta, S., et al.
Publicado: (2018)

Association of Concomitant Gestational Hypertensive Disorders and Gestational Diabetes With Cardiovascular Disease
por: Echouffo Tcheugui, Justin B., et al.
Publicado: (2022)

Breast Cancer Incidence After a False-Positive Mammography Result
por: Mao, Xinhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v97rs5unm8tsl2qbbve2rqmc4r